Browsing Tag
CML
2 posts
Why Enliven’s FDA alignment may matter as ELVN-001 moves toward Phase 3
Find out how Enliven’s ELVN-001 data and FDA alignment could reshape the next phase of chronic myeloid leukemia therapy.
Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears
Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.